News

NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., a unique immuno-oncology company developing next-generation synthetic bispecific compounds designed to emulate or enhance the … [Read more...] about Kleo Pharmaceuticals Appoints Thomas J. Lynch, Jr., MD, as Chairman of the Board

Finding a cure for cancer is personal for many working at Kleo Pharmaceuticals in New Haven. Doug Manion, MD, the company’s CEO, has lost friends and family to the disease, as has the company’s … [Read more...] about New Haven biotech honored for work developing cancer-fighting drugs

It looks like a blue-tinted coffee maker with a toaster tucked underneath. It sounds like an old-fashioned fax machine. In fact, it’s a FACS. Make that “Flourescent Activated Cell Sorting” … [Read more...] about Biotech Spinoff Attracts Kudos, $$, In Quest For Cancer Drug

U.S. Sen. Chris Murphy swung by Science Park to endorse a new generation of economic development — and political leadership — in a city booming with biotech business talent. Murphy spent the … [Read more...] about Murphy Endorses Biotech, BBQ, & Elicker

New Haven, Conn., August 08, 2019 – Kleo Pharmaceuticals, Inc. (Kleo), an immuno-oncology company developing next-generation synthetic bispecific compounds designed to emulate or enhance the activity … [Read more...] about Kleo Pharmaceuticals Announces Open-House Event To Celebrate Innovator of the Month Award

NEW HAVEN, Conn., June 18, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc. (Kleo), an immuno-oncology company developing next-generation synthetic bispecific compounds designed to emulate or enhance … [Read more...] about Kleo Pharmaceuticals Announces a CD38 Targeting Antibody Recruiting Molecule (ARM™) to Treat Multiple Myeloma as the First Clinical Candidate in its Partnership with PeptiDream